Avalyn Pharma Shares Jump After Faster-Than-Expected Enrollment in Phase 2b MIST Trial
Avalyn Pharma's stock rose markedly mid-day after the company said it completed target enrollment for its Phase 2b MIST trial of AP01, an inhaled pirfenidone formulation for progressive pulmonary fibrosis, ahead of schedule. The trial reached its 375-patient enrollment goal and retains additional patients in screening who remain eligible for random…